Maria Cozzi Mascolo
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease
- Where
- Rincon, GA
- NPI
- 1194793042
- Received
- $358,043 in 1,393 records, 2019 to 2025
- As principal investigator
- $2,307,413 of research payments to others in 776 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 286 | $121,256 |
| 2024 | General payment | 242 | $91,107 |
| 2023 | General payment | 247 | $102,979 |
| 2022 | General payment | 213 | $29,031 |
| 2021 | General payment | 154 | $9,623 |
| 2020 | General payment | 103 | $1,667 |
| 2019 | General payment | 148 | $2,377 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 125 | $276,575 |
| Travel and Lodging | 146 | $37,962 |
| Food and Beverage | 1,102 | $27,010 |
| Consulting Fee | 11 | $16,277 |
| Education | 9 | $218 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-29 | GlaxoSmithKline, LLC. | $16 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-12-29 | GlaxoSmithKline, LLC. | $1 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-12-18 | Electromed, Inc. | $12 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-12-17 | AstraZeneca Pharmaceuticals LP | $5,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-12-17 | GENZYME CORPORATION | $26 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-12-16 | AstraZeneca Pharmaceuticals LP | $1,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-12-11 | AstraZeneca Pharmaceuticals LP | $23 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-12-10 | Regeneron Healthcare Solutions, Inc. | $21 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-12-08 | AstraZeneca Pharmaceuticals LP | $1,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-12-08 | AstraZeneca Pharmaceuticals LP | $23 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-12-01 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-11-26 | Verona Pharma, Inc. | $14 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-11-26 | GlaxoSmithKline, LLC. | $12 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-11-25 | GENZYME CORPORATION | $9 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-11-24 | AstraZeneca Pharmaceuticals LP | $2,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-11-24 | AstraZeneca Pharmaceuticals LP | $450 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-11-24 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-11-20 | Grifols USA, LLC | $28 | Food and Beverage | In-kind items and services | Prolastin-C Liquid Biological, Pulmonology | 2025 | |
| 2025-11-19 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-11-17 | Regeneron Healthcare Solutions, Inc. | $23 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-11-13 | AstraZeneca Pharmaceuticals LP | $121 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-11-12 | AstraZeneca Pharmaceuticals LP | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-11-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18 | Food and Beverage | In-kind items and services | JASCAYD Drug, RESPIRATORY | 2025 | |
| 2025-11-11 | AstraZeneca Pharmaceuticals LP | $432 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-11-11 | AstraZeneca Pharmaceuticals LP | $86 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-11-11 | AstraZeneca Pharmaceuticals LP | $74 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-11-11 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-11-07 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-11-03 | GlaxoSmithKline, LLC. | $14 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-11-02 | GlaxoSmithKline, LLC. | $11 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-10-31 | GlaxoSmithKline, LLC. | $5 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-10-31 | GlaxoSmithKline, LLC. | $0 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-10-29 | Grifols USA, LLC | $25 | Food and Beverage | In-kind items and services | Prolastin-C Liquid Biological, Pulmonology | 2025 | |
| 2025-10-27 | AstraZeneca Pharmaceuticals LP | $28 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-10-24 | AstraZeneca Pharmaceuticals LP | $465 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-10-24 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-10-23 | Electromed, Inc. | $14 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-10-22 | GENZYME CORPORATION | $26 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-20 | AstraZeneca Pharmaceuticals LP | $1,850 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-10-20 | AstraZeneca Pharmaceuticals LP | $647 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-10-20 | AstraZeneca Pharmaceuticals LP | $382 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-10-20 | AstraZeneca Pharmaceuticals LP | $152 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-10-20 | AstraZeneca Pharmaceuticals LP | $129 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-10-20 | GENZYME CORPORATION | $82 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-20 | AstraZeneca Pharmaceuticals LP | $29 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-10-20 | AstraZeneca Pharmaceuticals LP | $24 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-10-17 | GENZYME CORPORATION | $284 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-10-16 | AstraZeneca Pharmaceuticals LP | $3,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-10-16 | Verona Pharma, Inc. | $28 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-10-15 | AstraZeneca Pharmaceuticals LP | $121 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-10-15 | PFIZER INC. | $18 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2025 | |
| 2025-10-14 | AstraZeneca Pharmaceuticals LP | $950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-10-14 | Insmed, Inc. | $12 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-10-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22 | Food and Beverage | In-kind items and services | JASCAYD Drug, RESPIRATORY | 2025 | |
| 2025-10-09 | AstraZeneca Pharmaceuticals LP | $1,850 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FASENRA Biological, Respiratory | 2025 | |
| 2025-10-08 | AstraZeneca Pharmaceuticals LP | $465 | Consulting Fee | Cash or cash equivalent | FASENRA Biological, Respiratory | 2025 | |
| 2025-10-08 | Regeneron Healthcare Solutions, Inc. | $33 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-07 | AstraZeneca Pharmaceuticals LP | $113 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-10-06 | AstraZeneca Pharmaceuticals LP | $25 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-10-02 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-10-02 | AstraZeneca Pharmaceuticals LP | $1,850 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-10-02 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-10-02 | Lilly USA, LLC | $13 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-10-01 | Avadel CNS Pharmaceuticals, LLC | $30 | Food and Beverage | In-kind items and services | LUMRYZ Drug, CENTRAL NERVOUS SYSTEM CNS NEUROLOGY | 2025 | |
| 2025-09-30 | AstraZeneca Pharmaceuticals LP | $950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FASENRA Biological, Respiratory | 2025 | |
| 2025-09-30 | AstraZeneca Pharmaceuticals LP | $22 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-09-29 | AstraZeneca Pharmaceuticals LP | $425 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-09-29 | AstraZeneca Pharmaceuticals LP | $212 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-09-29 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-25 | GENZYME CORPORATION | $31 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-25 | Merck Sharp & Dohme LLC | $21 | Food and Beverage | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | 2025 | |
| 2025-09-23 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FASENRA Biological, Respiratory | 2025 | |
| 2025-09-23 | AstraZeneca Pharmaceuticals LP | $125 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-09-23 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-09-22 | Grifols USA, LLC | $33 | Food and Beverage | In-kind items and services | Prolastin-C Liquid Biological, Pulmonology | 2025 | |
| 2025-09-18 | AstraZeneca Pharmaceuticals LP | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FASENRA Biological, Respiratory | 2025 | |
| 2025-09-18 | AstraZeneca Pharmaceuticals LP | $124 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-09-18 | Verona Pharma, Inc. | $20 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-09-18 | Insmed, Inc. | $11 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-09-17 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-09-17 | GENZYME CORPORATION | $32 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-16 | AstraZeneca Pharmaceuticals LP | $233 | Travel and Lodging | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-09-16 | AstraZeneca Pharmaceuticals LP | $215 | Travel and Lodging | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-09-16 | AstraZeneca Pharmaceuticals LP | $142 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-09-15 | GENZYME CORPORATION | $6,952 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-09-15 | Amgen Inc. | $20 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Inflammation | 2025 | |
| 2025-09-14 | AstraZeneca Pharmaceuticals LP | $260 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-09-14 | AstraZeneca Pharmaceuticals LP | $147 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-09-14 | AstraZeneca Pharmaceuticals LP | $63 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-09-11 | GlaxoSmithKline, LLC. | $16 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-09-10 | GENZYME CORPORATION | $389 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-09-10 | GENZYME CORPORATION | $342 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-09-10 | GENZYME CORPORATION | $152 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-09 | Regeneron Healthcare Solutions, Inc. | $23 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-04 | Amgen Inc. | $34 | Education | In-kind items and services | 2025 | ||
| 2025-09-03 | AstraZeneca Pharmaceuticals LP | $22 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-08-29 | Verona Pharma, Inc. | $23 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-08-28 | GlaxoSmithKline, LLC. | $14 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-08-27 | AstraZeneca Pharmaceuticals LP | $19 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-08-22 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-08-22 | Grifols USA, LLC | $21 | Food and Beverage | In-kind items and services | Prolastin-C Liquid Biological, Pulmonology | 2025 | |
| 2025-08-21 | Amgen Inc. | $7 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Inflammation | 2025 | |
| 2025-08-20 | GENZYME CORPORATION | $35 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-08-18 | HARMONY BIOSCIENCES LLC | $19 | Food and Beverage | In-kind items and services | WAKIX Drug, NARCOLEPSY | 2025 | |
| 2025-08-17 | AstraZeneca Pharmaceuticals LP | $349 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-08-17 | AstraZeneca Pharmaceuticals LP | $147 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-08-17 | AstraZeneca Pharmaceuticals LP | $118 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-08-15 | AstraZeneca Pharmaceuticals LP | $950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-08-15 | Insmed, Inc. | $17 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-08-15 | Insmed, Inc. | $16 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-08-14 | GlaxoSmithKline, LLC. | $21 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-08-14 | GlaxoSmithKline, LLC. | $0 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-08-12 | AstraZeneca Pharmaceuticals LP | $465 | Consulting Fee | Cash or cash equivalent | FASENRA Biological, Respiratory | 2025 | |
| 2025-08-11 | United Therapeutics Corporation | $18 | Food and Beverage | In-kind items and services | Tyvaso Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | 2025 | |
| 2025-08-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22 | Food and Beverage | In-kind items and services | OFEV Drug, RESPIRATORY | 2025 | |
| 2025-08-06 | AstraZeneca Pharmaceuticals LP | $950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-08-06 | Regeneron Healthcare Solutions, Inc. | $21 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-05 | Insmed, Inc. | $23 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-07-25 | AstraZeneca Pharmaceuticals LP | $950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-07-24 | Merck Sharp & Dohme LLC | $19 | Food and Beverage | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | 2025 | |
| 2025-07-23 | AstraZeneca Pharmaceuticals LP | $465 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-23 | Grifols USA, LLC | $29 | Food and Beverage | In-kind items and services | Prolastin-C Liquid Biological, Pulmonology | 2025 | |
| 2025-07-21 | GENZYME CORPORATION | $36 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-07-21 | Regeneron Healthcare Solutions, Inc. | $12 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-07-18 | Insmed, Inc. | $16 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-07-17 | AstraZeneca Pharmaceuticals LP | $23 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-07-17 | IDORSIA PHARMACEUTICALS US INC | $15 | Food and Beverage | In-kind items and services | Quviviq Drug, Insomnia | 2025 | |
| 2025-07-16 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-07-15 | GENZYME CORPORATION | $11 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-07-14 | Amgen Inc. | $21 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Inflammation | 2025 | |
| 2025-07-10 | AstraZeneca Pharmaceuticals LP | $3,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-07-10 | Actelion Pharmaceuticals US, Inc. | $38 | Food and Beverage | In-kind items and services | OPSYNVI Drug, Pulmonary Hypertension | 2025 | |
| 2025-07-10 | Verona Pharma, Inc. | $18 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-07-08 | AstraZeneca Pharmaceuticals LP | $180 | Travel and Lodging | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-07-08 | AstraZeneca Pharmaceuticals LP | $23 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-07-07 | Regeneron Healthcare Solutions, Inc. | $27 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-07-03 | AstraZeneca Pharmaceuticals LP | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-07-03 | AstraZeneca Pharmaceuticals LP | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FASENRA Biological, Respiratory | 2025 | |
| 2025-07-03 | JAZZ PHARMACEUTICALS INC. | $24 | Food and Beverage | In-kind items and services | XYWAV Drug, NEUROLOGY | 2025 | |
| 2025-07-03 | ANI Pharmaceuticals, Inc. | $21 | Food and Beverage | In-kind items and services | PURIFIED CORTROPHIN GEL Drug, Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | 2025 | |
| 2025-07-01 | AstraZeneca Pharmaceuticals LP | $950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-30 | GlaxoSmithKline, LLC. | $21 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-06-26 | Axsome Therapeutics, Inc. | $19 | Food and Beverage | In-kind items and services | Sunosi Drug, Neurology | 2025 | |
| 2025-06-25 | Electromed, Inc. | $11 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-06-23 | Grifols USA, LLC | $27 | Food and Beverage | In-kind items and services | Prolastin-C Liquid Biological, Pulmonology | 2025 | |
| 2025-06-19 | Verona Pharma, Inc. | $24 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-06-18 | GENZYME CORPORATION | $28 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-06-18 | GlaxoSmithKline, LLC. | $7 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-06-16 | Merck Sharp & Dohme LLC | $28 | Food and Beverage | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | 2025 | |
| 2025-06-11 | ANI Pharmaceuticals, Inc. | $21 | Food and Beverage | In-kind items and services | PURIFIED CORTROPHIN GEL Drug, Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | 2025 | |
| 2025-06-11 | AstraZeneca Pharmaceuticals LP | $13 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-06-06 | GlaxoSmithKline, LLC. | $28 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-06-06 | GlaxoSmithKline, LLC. | $18 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-06-04 | Regeneron Healthcare Solutions, Inc. | $30 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-06-02 | Amgen Inc. | $24 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Inflammation | 2025 | |
| 2025-06-02 | Inspire Medical Systems, Inc. | $17 | Food and Beverage | In-kind items and services | INSPIRE Device, NEUROLOGY | 2025 | |
| 2025-05-29 | AstraZeneca Pharmaceuticals LP | $23 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-05-28 | AstraZeneca Pharmaceuticals LP | $465 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-05-28 | AstraZeneca Pharmaceuticals LP | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-05-28 | Merck Sharp & Dohme LLC | $17 | Food and Beverage | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | 2025 | |
| 2025-05-27 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-05-27 | AstraZeneca Pharmaceuticals LP | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-05-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20 | Food and Beverage | In-kind items and services | OFEV Drug, RESPIRATORY | 2025 | |
| 2025-05-19 | AstraZeneca Pharmaceuticals LP | $950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-05-19 | GENZYME CORPORATION | $22 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-05-15 | Verona Pharma, Inc. | $21 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-05-14 | AstraZeneca Pharmaceuticals LP | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-05-14 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-05-13 | AstraZeneca Pharmaceuticals LP | $327 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-05-13 | AstraZeneca Pharmaceuticals LP | $304 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-05-13 | AstraZeneca Pharmaceuticals LP | $99 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-05-13 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-05-13 | Insmed, Inc. | $15 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-05-12 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-05-12 | Amgen Inc. | $20 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Inflammation | 2025 | |
| 2025-05-08 | AstraZeneca Pharmaceuticals LP | $124 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-05-07 | Regeneron Healthcare Solutions, Inc. | $29 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-05-05 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-04-30 | AstraZeneca Pharmaceuticals LP | $3,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-04-29 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20 | Food and Beverage | In-kind items and services | OFEV Drug, RESPIRATORY | 2025 | |
| 2025-04-28 | Regeneron Healthcare Solutions, Inc. | $35 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-04-28 | Insmed, Inc. | $15 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-04-28 | Regeneron Healthcare Solutions, Inc. | $2 | Education | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-04-24 | AstraZeneca Pharmaceuticals LP | $366 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-04-24 | AstraZeneca Pharmaceuticals LP | $276 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-04-24 | AstraZeneca Pharmaceuticals LP | $52 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-04-24 | Axsome Therapeutics, Inc. | $23 | Food and Beverage | In-kind items and services | Sunosi Drug, Neurology | 2025 | |
| 2025-04-24 | AstraZeneca Pharmaceuticals LP | $15 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-04-24 | Regeneron Healthcare Solutions, Inc. | $7 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-04-22 | AstraZeneca Pharmaceuticals LP | $122 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-04-22 | AstraZeneca Pharmaceuticals LP | $117 | Travel and Lodging | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-04-21 | GENZYME CORPORATION | $27 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-04-17 | Grifols USA, LLC | $21 | Food and Beverage | In-kind items and services | Prolastin-C Liquid Biological, Pulmonology | 2025 | |
| 2025-04-16 | ANI Pharmaceuticals, Inc. | $23 | Food and Beverage | In-kind items and services | PURIFIED CORTROPHIN GEL Drug, Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | 2025 | |
| 2025-04-14 | Merck Sharp & Dohme LLC | $21 | Food and Beverage | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | 2025 | |
| 2025-04-09 | Regeneron Healthcare Solutions, Inc. | $28 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-04-09 | Insmed, Inc. | $3 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-04-07 | AstraZeneca Pharmaceuticals LP | $44 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-04-07 | Verona Pharma, Inc. | $14 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-04-07 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 |
The latest 200 records of 1,393.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-19 | PFIZER INC. | CENTRICITY R RINCON PULMONOLOGY | $1,339 | AN INTERVENTIONAL PHASE 23 RANDOMIZED DOUBLEBLIND THIRD PARTYUNBLINDED PLACEBOCONTROLLED PARALLELGROUP STUDY TO INVESTIG | 2025 |
| 2025-12-04 | GlaxoSmithKline, LLC. | CR SERVICES ACQUISITION US LLC | $500 | A PROSPECTIVE COHORT STUDY OF PATIENTS WITH REFRACTORY OR UNEXPLAINED | 2025 |
| 2025-11-24 | JAZZ PHARMACEUTICALS INC. | Centricity Research Rincon Pulmonology | $1 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-11-24 | JAZZ PHARMACEUTICALS INC. | Centricity Research Rincon Pulmonology | $44 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-11-24 | JAZZ PHARMACEUTICALS INC. | Centricity Research Rincon Pulmonology | $60 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-11-24 | JAZZ PHARMACEUTICALS INC. | Centricity Research Rincon Pulmonology | $30 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-11-24 | JAZZ PHARMACEUTICALS INC. | Centricity Research Rincon Pulmonology | $3 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-11-24 | JAZZ PHARMACEUTICALS INC. | Centricity Research Rincon Pulmonology | $93 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-11-24 | JAZZ PHARMACEUTICALS INC. | Centricity Research Rincon Pulmonology | $45 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-11-24 | JAZZ PHARMACEUTICALS INC. | Centricity Research Rincon Pulmonology | $6 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-11-24 | JAZZ PHARMACEUTICALS INC. | Centricity Research Rincon Pulmonology | $2 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-11-24 | JAZZ PHARMACEUTICALS INC. | Centricity Research Rincon Pulmonology | $33 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-11-24 | JAZZ PHARMACEUTICALS INC. | Centricity Research Rincon Pulmonology | $1 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-11-24 | JAZZ PHARMACEUTICALS INC. | Centricity Research Rincon Pulmonology | $1 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-11-24 | JAZZ PHARMACEUTICALS INC. | Centricity Research Rincon Pulmonology | $0 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-11-24 | JAZZ PHARMACEUTICALS INC. | Centricity Research Rincon Pulmonology | $0 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-11-24 | JAZZ PHARMACEUTICALS INC. | Centricity Research Rincon Pulmonology | $30 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-11-07 | GlaxoSmithKline, LLC. | CR SERVICES ACQUISITION US LLC | $3,000 | A PROSPECTIVE COHORT STUDY OF PATIENTS WITH REFRACTORY OR UNEXPLAINED | 2025 |
| 2025-11-07 | GlaxoSmithKline, LLC. | CR SERVICES ACQUISITION US LLC | $2,500 | A PROSPECTIVE COHORT STUDY OF PATIENTS WITH REFRACTORY OR UNEXPLAINED | 2025 |
| 2025-11-07 | GlaxoSmithKline, LLC. | CR SERVICES ACQUISITION US LLC | $8,000 | A PROSPECTIVE COHORT STUDY OF PATIENTS WITH REFRACTORY OR UNEXPLAINED | 2025 |
| 2025-10-15 | JAZZ PHARMACEUTICALS INC. | CR Services Acquisition US, LLC | $3,300 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-10-13 | JAZZ PHARMACEUTICALS INC. | CR Services Acquisition US, LLC | $700 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-10-13 | JAZZ PHARMACEUTICALS INC. | CR Services Acquisition US, LLC | $1,359 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-10-13 | JAZZ PHARMACEUTICALS INC. | CR Services Acquisition US, LLC | $3,500 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-10-13 | JAZZ PHARMACEUTICALS INC. | CR Services Acquisition US, LLC | $800 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-10-13 | JAZZ PHARMACEUTICALS INC. | CR Services Acquisition US, LLC | $75 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-10-13 | JAZZ PHARMACEUTICALS INC. | CR Services Acquisition US, LLC | $250 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-10-13 | JAZZ PHARMACEUTICALS INC. | CR Services Acquisition US, LLC | $3,250 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-10-13 | JAZZ PHARMACEUTICALS INC. | CR Services Acquisition US, LLC | $2,479 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-10-13 | JAZZ PHARMACEUTICALS INC. | CR Services Acquisition US, LLC | $375 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-10-02 | JAZZ PHARMACEUTICALS INC. | CR Services Acquisition US, LLC | $1,320 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-10-02 | JAZZ PHARMACEUTICALS INC. | CR Services Acquisition US, LLC | $1,320 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-10-02 | JAZZ PHARMACEUTICALS INC. | CR Services Acquisition US, LLC | $86 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-10-02 | JAZZ PHARMACEUTICALS INC. | CR Services Acquisition US, LLC | $458 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-10-02 | JAZZ PHARMACEUTICALS INC. | CR Services Acquisition US, LLC | $3,622 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-10-02 | JAZZ PHARMACEUTICALS INC. | CR Services Acquisition US, LLC | $1,320 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-10-02 | JAZZ PHARMACEUTICALS INC. | CR Services Acquisition US, LLC | $1,320 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-10-02 | JAZZ PHARMACEUTICALS INC. | CR Services Acquisition US, LLC | $86 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-10-02 | JAZZ PHARMACEUTICALS INC. | CR Services Acquisition US, LLC | $214 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-10-02 | JAZZ PHARMACEUTICALS INC. | CR Services Acquisition US, LLC | $86 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-10-02 | JAZZ PHARMACEUTICALS INC. | CR Services Acquisition US, LLC | $86 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-10-02 | JAZZ PHARMACEUTICALS INC. | CR Services Acquisition US, LLC | $1,320 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-10-02 | JAZZ PHARMACEUTICALS INC. | CR Services Acquisition US, LLC | $1,431 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-10-01 | Verona Pharma, Inc. | CR SERVICES ACQUISITION US LLC | $2,300 | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | 2025 |
| 2025-09-30 | Insmed, Inc. | IACT Health - Roswell - IACT - HyperCore - PPDS | $48 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-08-27 | GlaxoSmithKline, LLC. | CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH | $1,000 | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | 2025 |
| 2025-08-20 | Genentech, Inc. | INSTITUTE FOR THE ADVANCEMENT | $3,493 | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety | 2025 |
| 2025-08-20 | Genentech, Inc. | INSTITUTE FOR THE ADVANCEMENT | $925 | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety | 2025 |
| 2025-08-20 | Genentech, Inc. | INSTITUTE FOR THE ADVANCEMENT | $800 | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety | 2025 |
| 2025-08-20 | Genentech, Inc. | INSTITUTE FOR THE ADVANCEMENT | $750 | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety | 2025 |
| 2025-08-12 | AstraZeneca Pharmaceuticals LP | CR SERVICES ACQUSITION US, LLC | $20,306 | Randomized Double blind Placebo controlled Parallel Group Multicenter Phase 3 Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-08-06 | JAZZ PHARMACEUTICALS INC. | CR Services Acquisition US, LLC | $1,000 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-08-01 | GlaxoSmithKline, LLC. | CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH | $800 | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | 2025 |
| 2025-08-01 | GlaxoSmithKline, LLC. | CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH | $1,750 | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | 2025 |
| 2025-08-01 | GlaxoSmithKline, LLC. | CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH | $700 | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | 2025 |
| 2025-08-01 | GlaxoSmithKline, LLC. | CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH | $1,750 | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | 2025 |
| 2025-08-01 | GlaxoSmithKline, LLC. | CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH | $1,000 | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | 2025 |
| 2025-08-01 | GlaxoSmithKline, LLC. | CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH | $5,500 | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | 2025 |
| 2025-07-30 | GlaxoSmithKline, LLC. | CR SERVICES ACQUISITION US LLC DBA CENTRICITY RESEARCH | $700 | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | 2025 |
| 2025-07-28 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $41 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-07-28 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $518 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-07-28 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $33 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-07-28 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $18 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-07-28 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $202 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-07-25 | Verona Pharma, Inc. | CR SERVICES ACQUISITION US LLC | $1,800 | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | 2025 |
| 2025-07-25 | Verona Pharma, Inc. | CR SERVICES ACQUISITION US LLC | $10,000 | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | 2025 |
| 2025-07-07 | JAZZ PHARMACEUTICALS INC. | CR Services Acquisition US, LLC | $275 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-07-07 | JAZZ PHARMACEUTICALS INC. | CR Services Acquisition US, LLC | $510 | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYW | 2025 |
| 2025-06-02 | SANOFI PASTEUR INC. | CR SERVICES ACQUISITION US LLC | $400 | A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactiv | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $27 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $202 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $41 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $18 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $33 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $33 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $33 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $33 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $50 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $25 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $202 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $33 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $27 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $26 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $33 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $18 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $36 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $32 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $32 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $32 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $26 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $33 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $18 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $33 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $33 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $33 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $18 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $41 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $33 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $26 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
| 2025-05-19 | Regeneron Pharmaceuticals, Inc. | CR SERVICES ACQUISITION US LLC | $18 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Rincon, GA, county Effingham County, GA, state Georgia; placed by its city name.
| Measure | Place (city or town) Rincon, GA | County Effingham County, GA | State Georgia |
|---|---|---|---|
| Population B01003 | 11,332 | 69,143 | 10,940,407 |
| Population, 2020 census P1 | 10,934 | 64,769 | 10,711,908 |
| Median age B01002 | 34.2 | 37.0 | 37.6 |
| Under 18 B01001 | 29.1% | 26.4% | 23.2% |
| 65 and over B01001 | 9.1% | 12.5% | 15.0% |
| Households B11001 | 4,376 | 24,287 | 4,074,366 |
| Foreign born B05002 | 7.0% | 4.2% | 11.2% |
| Median household income B19013 | $74,417 | $88,438 | $77,353 |
| Median family income B19113 | $91,477 | $99,697 | $93,754 |
| Per capita income B19301 | $36,730 | $38,913 | $40,924 |
| Poverty rate B17001 | 9.0% | 6.8% | 13.4% |
| Unemployment rate B23025 | 9.5% | 5.5% | 5.1% |
| Civilian labor force B23025 | 5,658 | 35,010 | 5,496,061 |
| Mean commute (minutes) B08013 | 28.7 | 32.3 | 28.3 |
| Bachelor's degree or higher B15003 | 25.2% | 27.2% | 34.9% |
| Housing units B25001 | 4,856 | 25,943 | 4,541,835 |
| Owner-occupied B25003 | 61.1% | 78.4% | 65.7% |
| Renters B25003 | 38.9% | 21.6% | 34.3% |
| Median home value B25077 | $251,600 | $276,000 | $303,300 |
| Median gross rent B25064 | $1,245 | $1,147 | $1,393 |
| White, not Hispanic B03002 | 62.8% | 72.9% | 49.1% |
| Black B03002 | 22.0% | 14.4% | 30.7% |
| Hispanic or Latino B03002 | 7.7% | 6.6% | 11.0% |
| Asian B03002 | 2.3% | 1.0% | 4.5% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 3.3% in Sep 2026 (3.4% a year earlier); per capita personal income $65,111 in 2025, up 26% in five years (+1.6% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Rincon, GA.
Comments